This company announces that AIA CA 19-9 and ST AIA CA 19-9 have received FDA clearance. This marker is used as an aid in monitoring response to therapy for patients with gastrointestinal cancer, primarily pancreatic cancer.
The assay correlates well with the RIA method by Fujirebio. It is cleared for use on this company’s AIA 600II, AIA NexIA and AIA600, and pending approval on the AIA1800 and Tomas Immunoassay Systems.
Reagents are packaged in two different configurations. The ST AIA CA 19-9 has a 10-minute incubation and is packaged in 100 tests/kit. The AIA CA 19-9 has a 40 minute incubation and is packaged in200 tests per kit. The Unit Dose test cup means no reagent waste, and minimizes consumables.
Tosoh Bioscience
www.CLPmag.com
Keywords: disease management, cancer
